Anebulo Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANEB research report →
Companywww.anebulo.com
Anebulo Pharmaceuticals, Inc. , a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose.
- CEO
- Richard Anthony Cunningham
- IPO
- 2021
- Employees
- 2
- HQ
- Lakeway, TX, US
Price Chart
Valuation
- Market Cap
- $20.19M
- P/E
- -2.55
- P/S
- 0.00
- P/B
- 2.56
- EV/EBITDA
- -1.34
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -74.58%
- ROIC
- -102.66%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-8,484,763 · -3.45%
- EPS
- $-0.25 · 21.88%
- Op Income
- $-9,223,481
- FCF YoY
- 21.52%
Performance & Tape
- 52W High
- $3.42
- 52W Low
- $0.30
- 50D MA
- $0.62
- 200D MA
- $1.56
- Beta
- -1.94
- Avg Volume
- 35.06K
Get TickerSpark's AI analysis on ANEB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 4, 25 | Lawler Joseph F. | other | 25,000 |
| Apr 4, 25 | Lawler Joseph F. | other | 13,236 |
| Apr 4, 25 | SHAH BIMAL R. | other | 25,000 |
| Apr 4, 25 | SHAH BIMAL R. | other | 6,618 |
| Apr 4, 25 | Cundy Kenneth C | other | 115,037 |
| Apr 4, 25 | Aryeh Jason | other | 25,000 |
| Apr 4, 25 | Aryeh Jason | other | 4,964 |
| Apr 4, 25 | Cunningham, Richard Anthony | other | 316,352 |
| Apr 4, 25 | Lin Kenneth | other | 25,000 |
| Apr 4, 25 | Lin Kenneth | other | 4,964 |
Our ANEB Coverage
We haven't published any research on ANEB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ANEB Report →